Pharmaceutical company Reckitt Benckiser has applied to drug regulator Medsafe to reclassify pseudoephedrine so that small, single-day packets of the nasal decongestant can sit on open pharmacy shelves alongside everyday painkillers like Panadol and Ibuprofen. According to Reckitt’s application, retail cold and flu remedies no longer pose a precursor risk for illegal methamphetamine production because criminal gangs now rely on bulk overseas importations.
Current Pseudoephedrine Regulations in New Zealand
Right now, pseudoephedrine is classified as a restricted medicine in pharmacies. Customers cannot browse open shelves for the pills. Instead, they must specifically ask a pharmacist, who assesses each buyer’s suitability before completing the sale. This system has been in place following years of strict controls designed to curb the illicit manufacture of methamphetamine, commonly known as P.
The drug was originally relegated to prescription-only status back in 2011 due to widespread domestic conversion of cold remedies into illicit drugs. However, the regulatory landscape shifted in 2024 when the medicine returned to its current restricted pharmacy status. That change followed a political push from ACT’s David Seymour, who campaigned on the issue ahead of the general election.
Reckitt Benckiser’s Self-Selection Proposal for Cold Medicines
Under the new proposal submitted by Reckitt Benckiser, pharmacies would stock single-day pill packets on open shelves. Shoppers could select the product themselves without needing an initial consultation with a pharmacist. However, sales would remain strictly within pharmacy walls, excluding supermarkets and convenience stores.
According to Reckitt’s filing, the reclassification aims to solve two major issues: granting consumers easier access to an effective nasal decongestant and reducing the administrative workload on busy pharmacy staff. When pseudoephedrine disappeared from open shelves in 2011, many pharmaceutical brands reformulated their cold and flu products to use phenylephrine instead.
Shifting Drug Enforcement Realities and Methamphetamine Supply
Reckitt’s application argues that heavy restrictions failed to control the broader supply and use of methamphetamine in New Zealand. The company states that the drug market has evolved past the era of small-scale kitchen labs that relied on pharmacy-sourced pills.
“The supply and manufacture of methamphetamine use in New Zealand has shifted from small scale production, where pharmacy sourced pseudoephedrine was the main precursor used,” the application noted. Instead, law enforcement faces “large scale clandestine manufacture” driven by raw ingredients brought in from overseas or the bulk importation of finished methamphetamine.
Did You Know?
Before pseudoephedrine restrictions took effect in 2011, New Zealand pharmacies routinely monitored large purchases of cold medications. The 2024 reclassification to restricted status allowed pharmacists to sell the medicine again after a consultation, paving the way for Reckitt’s current push toward self-selection.
Next Steps in the Medsafe Review Process
Medsafe’s Medicines Classification Committee will formally discuss Reckitt Benckiser’s application during its upcoming meeting next month.
Public submissions regarding the potential return of over-the-counter pseudoephedrine remain open until 5 October. Following the consultation window, the committee will evaluate the feedback before issuing a recommendation on whether to ease purchase restrictions.
Frequently Asked Questions
Can I buy pseudoephedrine at supermarkets if the proposal passes?
No. Under the proposal, small single-day packets would only be available for self-selection on open shelves inside registered pharmacies, not at supermarkets or general retail stores.
When will Medsafe make a decision?
Medsafe’s Medicines Classification Committee will discuss the application next month, following a public submission period that closes on 5 October.
Why was pseudoephedrine restricted in the first place?
Authorities restricted the medicine to prescription-only status in 2011 because criminals were using it as a chemical precursor to manufacture methamphetamine.
Join the Conversation
What are your thoughts on returning pseudoephedrine to open pharmacy shelves? Share your perspective in the comments below, or subscribe to our newsletter for the latest updates on New Zealand health regulations.
Worth a look